Professional technology integration to support the entire R&D process

NPFFR2 (Neuropeptide FF receptor 2) is an important class A G protein-coupled receptor (GPCR) widely distributed in central and peripheral tissues, belonging to the RF-amide peptide receptor family. It profoundly regulates pain sensation, opioid tolerance, energy metabolism, emotional behavior, stress response, and feeding behavior, making it a highly promising therapeutic target for chronic pain, metabolic disorders, anxiety, and drug addiction.

For a long time, the ligand recognition mode, subtype selectivity, and activation mechanism of NPFFR2 have remained unclear, severely restricting targeted drug development. In 2025, a team led by Xu Huaqiang from the School of Pharmacy at Shanghai Jiao Tong University, Lingang Laboratory, and the Chinese Academy of Sciences jointly published groundbreaking results in Cell Reports, using cryo-electron microscopy to resolve for the first time the fine structure of NPFFR2 bound to endogenous neuropeptides, revealing the molecular mechanisms of ligand recognition, subtype specificity, and receptor activation, and laying a structural foundation for precision drug design.

Key Points

• NPFFR2 is a core GPCR target that integrates neuro-regulation and metabolic control, playing a key role in pain, anxiety, energy homeostasis, and weight regulation.
• NPFFR2 is activated by endogenous ligands NPFF, NPVF, and PrRP, and primarily couples with Gi/o protein signaling.
• Structural resolution of NPFFR2 in 2025 has clarified ligand recognition and activation, accelerating structure-based drug design.
• NPFFR2 agonists achieve weight loss by promoting fatty acid oxidation, independent of appetite suppression, and can avoid common side effects of GLP-1 drugs.
• Representative drug in clinical pipeline: Novo Nordisk NN501 (PrRP analog), which exerts anti-obesity effects via NPFFR2/GPR10.
• Recombinant NPFFR2 reporter gene cell models enable reliable agonist screening, EC50 determination, cAMP inhibition assays, and mechanistic studies.
• Validated cell models improve experimental reproducibility and support high-throughput screening for pain, metabolic, and weight loss drugs.

Why NPFFR2 is a high-value drug target

NPFFR2 sits at the intersection of neural and metabolic regulation, addressing significant unmet clinical needs.

Under normal physiological conditions, NPFFR2 regulates:

• Pain and opioid tolerance: modulating nociception and reducing opioid-induced hyperalgesia
• Stress and emotion: activating the HPA axis and regulating anxiety-like behavior
• Energy metabolism: enhancing fatty acid oxidation, controlling thermogenesis, and regulating body weight
• Homeostatic functions: food intake, blood pressure, reproduction, immunity, and motor control

NPFFR2 abnormalities are closely associated with chronic pain, opioid addiction, obesity, diabetes, anxiety, and metabolic syndrome. NPFFR2 is a star target for multiple indications with strong translational potential.

NPFFR2 signaling pathways

NPFFR1 and NPFFR2 belong to the RF-amide peptide GPCR family and are activated by the endogenous neuropeptides NPFF and NPVF.

1. Gi/o Signaling (Primary Pathway)

NPFFR2 primarily couples with Gi/o proteins, inhibits adenylyl cyclase, reduces intracellular cAMP, and mediates analgesia, emotional regulation, and metabolic reprogramming.

2. Downstream Physiological Effects

Activation of NPFFR2 achieves:

• Inhibition of pain transmission and regulation of opioid tolerance
• Activation of the HPA axis and regulation of stress-related emotional responses
• Enhancement of fatty acid oxidation and increase in energy expenditure
• Regulate food intake and body weight homeostasis

3. Cross-regulation with the PrRP–GPR10 axis

Prolactin-releasing peptide (PrRP) is an endogenous ligand for GPR10 and can also activate NPFFR2. PrRP and its analogs achieve anti-obesity effects by increasing fatty acid oxidation rather than suppressing appetite, representing a novel metabolic pharmacological mechanism.

R&D applications supported by NPFFR2 research tools

High-quality NPFFR2 tools can support systematic drug discovery and mechanism exploration:

• Receptor expression and ligand-receptor interaction analysis
• Agonist activity and EC50 determination
• Gi/o-mediated cAMP inhibition assays
• High-throughput screening of agonists/antagonists
• Methodological validation, reproducibility, and stability testing
• Receptor activation and signaling mechanism research
• Preclinical candidate compound screening and optimization

Table 1. key features of stable NPFFR2 cell models

Clinical drug development targeting NPFFR2

NPFFR2 is rapidly moving from basic research to clinical translation, with particularly prominent progress in the field of metabolic diseases.

Representative drug: NN501 (Novo Nordisk)

• PrRP analog, activates NPFFR2/GPR10
• Mechanism of action: Enhances fatty acid oxidation, does not suppress appetite
• Advantages: No GLP-1-like gastrointestinal side effects, weight loss is not prone to rebound
• Indications: Obesity, metabolic disorders

Other research directions:

• Small molecule agonists/antagonists for pain and anxiety
• Dual-target modulators targeting NPFFR2 and metabolic pathways
• Peptide drugs with better stability and subtype selectivity

Why recombinant NPFFR2 cell models are indispensable

NPFFR2 drug R&D requires stable, quantitative, and physiologically relevant functional assay systems. Recombinant cell lines solve core pain points:

• Eliminate individual variability of primary tissues
• Enable stable, long-term signaling research
• Support both reporter gene and cAMP inhibition assays
• Provide reliable EC50 for agonist screening
• Compatible with high-throughput and high-content screening platforms

Widely used for:

• Agonist screening and lead compound discovery
• Quantitative activity evaluation (EC50)
• Gi/o protein-mediated cAMP inhibition assay
• Receptor pharmacology and mechanism studies
• Early drug candidate validation

Core NPFFR2 cell model for drug R&D

NPFFR2 NFAT-Luc HEK293 Cell Line (C38)

• Stable expression of full-length human NPFFR2
• Coupled to physiological Gi/o signaling pathways
• Validated using NFAT-luciferase reporter system
• Supports agonist dose-response relationship and EC50 determination
• Compatible with HTRF cAMP inhibition assays
• Robust response to agonists such as Neuropeptide AF and Neuropeptide FF
• High reproducibility, suitable for high-throughput and routine research

Application of NPFFR2 cell models in the R&D workflow

NPFFR2 cell models throughout the drug R&D process:

1. Target validation: Confirm receptor expression and functional signaling

2. High-throughput screening: Identify agonist/antagonist lead compounds

3. Activity evaluation: Determine EC50 and rank candidate molecules

4. Mechanism research: Analyze cAMP inhibition and pathway activation

5. Method optimization: Establish stable and reproducible quality control methods

6. Lead optimization: Support structure-activity relationship (SAR) studies

The ultimate goal is to produce reliable, quantitative, and reproducible research and publication data for pain, anxiety, and metabolic disease drug development.

How to choose a suitable NPFFR2 cell model

Choose according to experimental requirements:

1. Requires Gi/o coupling functional response → Choose NPFFR2 NFAT-Luc HEK293

2. Requires cAMP inhibition experiment → Choose HTRF-compatible validated clones

3. Prioritize systems with stable expression and high reproducibility

4. Ensure compatibility with luminescence or HTRF detection platforms

5. Select monoclonal cell lines with complete characterization to reduce experimental variability

Summary

NPFFR2 is a powerful neuro-metabolic dual switch and a high-potential target for treating pain, anxiety, opioid addiction, and obesity. The 2025 Cell Reports structural breakthrough has opened a new era of structure-based rational drug design.

To achieve efficient and reliable drug R&D, researchers require rigorously validated stable NPFFR2 cell models to support agonist screening, cAMP inhibition, EC50 quantification, and mechanistic studies. These tools bridge structural biology and drug development, accelerating hit compound discovery, strengthening candidate optimization, and promoting clinical translation.

Q&A

1. Q: What is the core physiological function of NPFFR2?

A: NPFFR2 is a neuro-metabolic dual-regulatory GPCR that regulates pain, anxiety, opioid tolerance, energy metabolism, fatty acid oxidation, and body weight.

2. Q: Why is NPFFR2 an ideal drug target?

A: It covers high unmet need areas such as chronic pain, anxiety, opioid addiction, and obesity, and its weight-loss mechanism does not rely on appetite suppression, offering significant safety advantages.

3. Q: What is the main signaling pathway of NPFFR2?

A: NPFFR2 primarily couples with Gi/o proteins, inhibits adenylyl cyclase, and reduces intracellular cAMP, thereby regulating downstream physiological responses.

4.Q: What are the advantages of the NPFFR2-targeted weight-loss drug NN501?

A: NN501 promotes weight loss by enhancing fatty acid oxidation, does not suppress appetite, lacks the gastrointestinal side effects associated with GLP-1 drugs, and is less prone to rebound.

5.Q: What are NPFFR2 cell models primarily used for?

A: They are used for agonist screening, EC50 determination, cAMP inhibition experiments, functional validation, high-throughput screening, and drug mechanism studies.